Clinical Trial Results: Malignant Melanoma

Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.

Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Fortemustine in Patients With Metastatic Melanoma.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 10/1/2007
Phase: II
Phase II Randomized Dose-Finding Study of Subcutaneous Administration of Three Different Doses of Pegylated Interferon alfa-2a in Patients With Metastatic Malignant Melanoma (MM).